{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:29:54Z","timestamp":1781713794449,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41380-026-03451-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:23:49Z","timestamp":1770722629000},"page":"3216-3228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3082-8104","authenticated-orcid":false,"given":"Cyril","family":"Gerolymos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Garosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-6622","authenticated-orcid":false,"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-9948","authenticated-orcid":false,"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9401-3586","authenticated-orcid":false,"given":"Mika","family":"Gavaudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-2030","authenticated-orcid":false,"given":"Guillaume","family":"Fond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"3451_CR1","unstructured":"Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American psychiatric association; 2013."},{"key":"3451_CR2","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3390\/diagnostics11112142","volume":"11","author":"P Bozzatello","year":"2021","unstructured":"Bozzatello P, Garbarini C, Rocca P, Bellino S. Borderline personality disorder: Risk factors and early detection. Diagnostics. 2021;11:2142.","journal-title":"Diagnostics"},{"key":"3451_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/wps.21156","volume":"23","author":"F Leichsenring","year":"2024","unstructured":"Leichsenring F, Fonagy P, Heim N, Kernberg OF, Leweke F, Luyten P, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23:4\u201325.","journal-title":"World Psychiatry"},{"key":"3451_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/wps.20128","volume":"13","author":"E Chesney","year":"2014","unstructured":"Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153\u201360.","journal-title":"World Psychiatry"},{"key":"3451_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/cpp.2888","volume":"30","author":"L De Freixo Ferreira","year":"2023","unstructured":"De Freixo Ferreira L, Guerra C, Vieira\u2010Coelho MA. Predictors of psychotherapy dropout in patients with borderline personality disorder: A systematic review. Clin Psychol Psychother. 2023;30:1324\u201337.","journal-title":"Clin Psychol Psychother"},{"key":"3451_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1521\/pedi_2013_27_106","volume":"27","author":"S Wnuk","year":"2013","unstructured":"Wnuk S, McMain S, Links PS, Habinski L, Murray J, Guimond T. Factors related to dropout from treatment in two outpatient treatments for borderline personality disorder. J Personal Disord. 2013;27:716\u201326.","journal-title":"J Personal Disord"},{"key":"3451_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/brainsci13060878","volume":"13","author":"I Messina","year":"2023","unstructured":"Messina I, Spataro P, Sorella S, Grecucci A. \u201cHolding in Anger\u201d as a mediator in the relationship between attachment orientations and borderline personality features. Brain Sci. 2023;13:878.","journal-title":"Brain Sci"},{"key":"3451_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/07067437231213558","volume":"69","author":"A Sarmiento","year":"2024","unstructured":"Sarmiento A, Dean OM, Kavanagh BE, Mohebbi M, Berk M, Dodd S, et al. The influence of personality disorder symptoms on treatment outcomes in bipolar disorder: A secondary analysis of a randomised controlled trial: L\u2019influence des sympt\u00f4mes du trouble de la personnalit\u00e9 sur les r\u00e9sultats du traitement dans le trouble bipolaire: Une analyse secondaire d\u2019un essai randomis\u00e9 contr\u00f4l\u00e9. Can J Psychiatry. 2024;69:275\u201387.","journal-title":"Can J Psychiatry"},{"key":"3451_CR9","first-page":"205","volume":"4","author":"TE Smith","year":"1995","unstructured":"Smith TE, Koenigsberg HW, Yeomans FE, Clarkin JF, Selzer MA. Predictors of dropout in psychodynamic psychotherapy of borderline personality disorder. J Psychother Pract Res. 1995;4:205\u201313.","journal-title":"J Psychother Pract Res"},{"key":"3451_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jbtep.2007.11.006","volume":"39","author":"N R\u00fcsch","year":"2008","unstructured":"R\u00fcsch N, Schiel S, Corrigan PW, Leihener F, Jacob GA, Olschewski M, et al. Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder. J Behav Ther Exp Psychiatry. 2008;39:497\u2013503.","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"3451_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1521\/pedi.2007.21.5.457","volume":"21","author":"J Paris","year":"2007","unstructured":"Paris J. The nature of borderline personality disorder: multiple dimensions, multiple symptoms, but one category. J Personal Disord. 2007;21:457\u201373.","journal-title":"J Personal Disord"},{"key":"3451_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","volume":"35","author":"G Gartlehner","year":"2021","unstructured":"Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. 2021;35:1053\u201367.","journal-title":"CNS Drugs"},{"key":"3451_CR13","doi-asserted-by":"crossref","unstructured":"Stoffers-Winterling JM, Storeb\u00f8 OJ, Pereira Ribeiro J, Kongerslev MT, V\u00f6llm BA, Mattivi JT, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Developmental, Psychosocial and Learning Problems Group, editor. Cochrane Database Syst Rev [Internet]. 2022 Nov 14 [cited 2024 Sept 26];2022(11). Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD012956.pub2.","DOI":"10.1002\/14651858.CD012956.pub2"},{"key":"3451_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.64719\/pb.4375","volume":"50","author":"M Pahwa","year":"2020","unstructured":"Pahwa M, Nu\u00f1ez NA, Joseph B, Seshadri A, Gerberi DJ, Frye MA, et al. Efficacy and tolerability of lamotrigine in borderline personality disorder: A systematic review and meta-analysis. Psychopharmacol Bull. 2020;50:118\u201336.","journal-title":"Psychopharmacol Bull"},{"key":"3451_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11126-023-10045-8","volume":"94","author":"G Valdivieso-Jim\u00e9nez","year":"2023","unstructured":"Valdivieso-Jim\u00e9nez G, Pino-Zavaleta DA, Campos-Rodriguez SK, Ortiz-Saavedra B, Fern\u00e1ndez MF, Benites-Zapata VA. Efficacy and safety of aripiprazole in borderline personality disorder: A systematic review. Psychiatr Q. 2023;94:541\u201357.","journal-title":"Psychiatr Q"},{"key":"3451_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1192\/bjp.2024.172","volume":"226","author":"J Pereira Ribeiro","year":"2025","unstructured":"Pereira Ribeiro J, Juul S, Kongerslev MT, J\u00f8rgensen MS, V\u00f6llm BA, Edemann-Callesen H, et al. Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses. Br J Psychiatry. 2025;226:226\u201337.","journal-title":"Br J Psychiatry"},{"key":"3451_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3451_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3451_CR19","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","volume":"381","author":"A Izcovich","year":"2023","unstructured":"Izcovich A, Chu DK, Mustafa RA, Guyatt G, Brignardello-Petersen R. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ. 2023;381:e074495.","journal-title":"BMJ"},{"key":"3451_CR20","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim SJ, Lee J, R\u00fccker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013.","journal-title":"Epidemiol Health"},{"key":"3451_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01075-y","volume":"20","author":"G R\u00fccker","year":"2020","unstructured":"R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Riley RD, Schwarzer G. The statistical importance of a study for a network meta-analysis estimate. BMC Med Res Methodol. 2020;20:190.","journal-title":"BMC Med Res Methodol"},{"key":"3451_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"3451_CR23","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","volume":"150","author":"JR Cornelius","year":"1993","unstructured":"Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843\u20138.","journal-title":"Am J Psychiatry"},{"key":"3451_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4088\/JCP.v69n0617","volume":"69","author":"MM Linehan","year":"2008","unstructured":"Linehan MM, McDavid JD, Brown MZ, Sayrs JHR, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:999\u20131005.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/sj.npp.1300153","volume":"28","author":"E Hollander","year":"2003","unstructured":"Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al. Divalproex in the treatment of impulsive aggression: Efficacy in Cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186\u201397.","journal-title":"Neuropsychopharmacology"},{"key":"3451_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4088\/JCP.v65n0704","volume":"65","author":"MC Zanarini","year":"2004","unstructured":"Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903\u20137.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","volume":"193","author":"SC Schulz","year":"2008","unstructured":"Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485\u201392.","journal-title":"Br J Psychiatry"},{"key":"3451_CR28","doi-asserted-by":"crossref","unstructured":"Reich DB, Zanarini MC, Bieri KA A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder: Int Clin Psychopharmacol. 2009;24:270\u20135.","DOI":"10.1097\/YIC.0b013e32832d6c2f"},{"key":"3451_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","volume":"72","author":"MC Zanarini","year":"2011","unstructured":"Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12-Week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353\u201362.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4088\/JCP.v65n0118","volume":"65","author":"MP Bogenschutz","year":"2004","unstructured":"Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104\u20139.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.v62n1103","volume":"62","author":"MC Zanarini","year":"2001","unstructured":"Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849\u201354.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","volume":"45","author":"RW Cowdry","year":"1988","unstructured":"Cowdry RW. Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111.","journal-title":"Arch Gen Psychiatry"},{"key":"3451_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","volume":"9","author":"PH Soloff","year":"1989","unstructured":"Soloff PH, George A, Nathan RS, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238.","journal-title":"J Clin Psychopharmacol"},{"key":"3451_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","volume":"50","author":"PH Soloff","year":"1993","unstructured":"Soloff PH. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377.","journal-title":"Arch Gen Psychiatry"},{"key":"3451_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0924-977X(94)90296-8","volume":"4","author":"J De La Fuente","year":"1994","unstructured":"De La Fuente J, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479\u201386.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3451_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1176\/appi.ajp.160.1.167","volume":"160","author":"MC Zanarini","year":"2003","unstructured":"Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167\u20139.","journal-title":"Am J Psychiatry"},{"key":"3451_CR37","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","volume":"159","author":"T Rinne","year":"2002","unstructured":"Rinne T, Van Den Brink W, Wouters L, Van Dyck R. SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048\u201354.","journal-title":"Am J Psychiatry"},{"key":"3451_CR38","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.4088\/JCP.v65n1112","volume":"65","author":"MK Nickel","year":"2004","unstructured":"Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515\u20139.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","volume":"57","author":"MK Nickel","year":"2005","unstructured":"Nickel MK, Nickel C, Kaplan P, Lahmann C, M\u00fchlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495\u20139.","journal-title":"Biol Psychiatry"},{"key":"3451_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.4088\/JCP.v65n1018","volume":"65","author":"A Philipsen","year":"2004","unstructured":"Philipsen A, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004;65:1414\u20139.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR41","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","volume":"162","author":"J Soler","year":"2005","unstructured":"Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al. Double-Blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221\u20134.","journal-title":"Am J Psychiatry"},{"key":"3451_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881105051540","volume":"19","author":"K Tritt","year":"2005","unstructured":"Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol (Oxf). 2005;19:287\u201391.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"3451_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","volume":"26","author":"TH Loew","year":"2006","unstructured":"Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al. Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"3451_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","volume":"163","author":"MK Nickel","year":"2006","unstructured":"Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833\u20138.","journal-title":"Am J Psychiatry"},{"key":"3451_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22170","volume":"22","author":"MJ Crawford","year":"2018","unstructured":"Crawford MJ, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, et al. Lamotrigine for people with borderline personality disorder: a RCT. Health Technol Assess. 2018;22:1\u201368.","journal-title":"Health Technol Assess"},{"key":"3451_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.v69n0412","volume":"69","author":"JC Pascual","year":"2008","unstructured":"Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, et al. Ziprasidone in the treatment of borderline personality disorder: A double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69:603\u20138.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR47","first-page":"38","volume":"25","author":"SS Shafti","year":"2015","unstructured":"Shafti SS, Kaviani H. A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder. Klin Psikofarmakol B\u00fcl-Bull Clin Psychopharmacol. 2015;25:38\u201343.","journal-title":"Klin Psikofarmakol B\u00fcl-Bull Clin Psychopharmacol"},{"key":"3451_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JCP.0b013e3181c826ff","volume":"30","author":"SS Shafti","year":"2010","unstructured":"Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: A randomized double-blind trial. J Clin Psychopharmacol. 2010;30:44\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"3451_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/104012371202400402","volume":"24","author":"R Moen","year":"2012","unstructured":"Moen R, Freitag M, Miller M, Lee S, Romine A, Song S, et al. Efficacy of extended-release divalproex combined with \u2018condensed\u2019 dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2012;24:255\u201360.","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"key":"3451_CR50","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","volume":"171","author":"DW Black","year":"2014","unstructured":"Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171:1174\u201382.","journal-title":"Am J Psychiatry"},{"key":"3451_CR51","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40263-017-0458-4","volume":"31","author":"P Bozzatello","year":"2017","unstructured":"Bozzatello P, Rocca P, Uscinska M, Bellino S. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: An open-label randomized controlled trial. CNS Drugs. 2017;31:809\u201319.","journal-title":"CNS Drugs"},{"key":"3451_CR52","doi-asserted-by":"publisher","first-page":"204512532210908","DOI":"10.1177\/20451253221090832","volume":"12","author":"MJ Crawford","year":"2022","unstructured":"Crawford MJ, Leeson VC, Evans R, Barrett B, McQuaid A, Cheshire J, et al. The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial. Ther Adv Psychopharmacol. 2022;12:204512532210908.","journal-title":"Ther Adv Psychopharmacol"},{"key":"3451_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/YIC.0000000000000219","volume":"33","author":"HZ Gvirts","year":"2018","unstructured":"Gvirts HZ, Lewis YD, Dvora S, Feffer K, Nitzan U, Carmel Z, et al. The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit\/hyperactivity disorder. Int Clin Psychopharmacol. 2018;33:233\u20137.","journal-title":"Int Clin Psychopharmacol"},{"key":"3451_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40263-018-0506-8","volume":"32","author":"J Kulkarni","year":"2018","unstructured":"Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Grigg J, Tan R, et al. Effect of the Glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: An exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs. 2018;32:179\u201387.","journal-title":"CNS Drugs"},{"key":"3451_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/bjp.2021.159","volume":"220","author":"JE Grant","year":"2022","unstructured":"Grant JE, Valle S, Chesivoir E, Ehsan D, Chamberlain SR. A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder. Br J Psychiatry. 2022;220:58\u201363.","journal-title":"Br J Psychiatry"},{"key":"3451_CR56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","volume":"54","author":"EF Coccaro","year":"1997","unstructured":"Coccaro EF. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54:1081.","journal-title":"Arch Gen Psychiatry"},{"key":"3451_CR57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4088\/JCP.v65n0314","volume":"65","author":"EB Simpson","year":"2004","unstructured":"Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379\u201385.","journal-title":"J Clin Psychiatry"},{"key":"3451_CR58","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1527-3458.2008.00041.x","volume":"14","author":"RP Shank","year":"2008","unstructured":"Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14:120\u201342.","journal-title":"CNS Neurosci Ther"},{"key":"3451_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s43440-023-00448-6","volume":"75","author":"Y Odagaki","year":"2023","unstructured":"Odagaki Y, Mikami M, Kinoshita M, Meana JJ, Callado LF, Garc\u00eda-Sevilla JA, et al. Agonistic properties of a series of psychotropic drugs at 5-HT1A receptors in rat and human brain membranes determined by [35S]GTP\u03b3S binding assay. Pharmacol Rep. 2023;75:266\u201375.","journal-title":"Pharmacol Rep"},{"key":"3451_CR60","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1517\/13543784.16.6.771","volume":"16","author":"M Wood","year":"2007","unstructured":"Wood M, Reavill C. Aripiprazole acts as a selective dopamine D 2 receptor partial agonist. Expert Opin Investig Drugs. 2007;16:771\u20135.","journal-title":"Expert Opin Investig Drugs"},{"key":"3451_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17460441.2019.1553951","volume":"14","author":"ASD Miranda","year":"2019","unstructured":"Miranda ASD, Miranda ASD, Teixeira AL. Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. Expert Opin Drug Discov. 2019;14:179\u201390.","journal-title":"Expert Opin Drug Discov"},{"key":"3451_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106452","volume":"167","author":"K Fukushima","year":"2020","unstructured":"Fukushima K, Hatanaka K, Sagane K, Ido K. Inhibitory effect of anti-seizure medications on ionotropic glutamate receptors: special focus on AMPA receptor subunits. Epilepsy Res. 2020;167:106452.","journal-title":"Epilepsy Res"},{"key":"3451_CR63","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/life12101645","volume":"12","author":"AS Correia","year":"2022","unstructured":"Correia AS, Silva I, Oliveira JC, Reguengo H, Vale N. Serotonin Type 3 receptor is potentially involved in cellular stress induced by hydrogen peroxide. Life. 2022;12:1645.","journal-title":"Life"},{"key":"3451_CR64","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00204-023-03489-1","volume":"97","author":"Y Wang","year":"2023","unstructured":"Wang Y, Chen Y, Chen Y, Luo W, Liu Y. Induction of clastogenesis and gene mutations by carbamazepine (at its therapeutically effective serum levels) in mammalian cells and the dependence on human CYP2B6 enzyme activity. Arch Toxicol. 2023;97:1753\u201364.","journal-title":"Arch Toxicol"},{"key":"3451_CR65","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/17425255.2014.908185","volume":"10","author":"L Citrome","year":"2014","unstructured":"Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10:893\u2013903.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3451_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2017.16040419","volume":"175","author":"A Szegedi","year":"2018","unstructured":"Szegedi A, Durgam S, Mackle M, Yu SY, Wu X, Mathews M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry. 2018;175:71\u20139.","journal-title":"Am J Psychiatry"},{"key":"3451_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-018-1842-x","volume":"18","author":"A Macfarlane","year":"2018","unstructured":"Macfarlane A, Greenhalgh T. Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach? BMC Pregnancy Childbirth. 2018;18:200.","journal-title":"BMC Pregnancy Childbirth"},{"key":"3451_CR68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/ajp.142.1.98","volume":"142","author":"DL Gardner","year":"1985","unstructured":"Gardner DL. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry. 1985;142:98\u2013100.","journal-title":"Am J Psychiatry"},{"key":"3451_CR69","first-page":"555","volume-title":"Borderline personality disorder: treatment and management","author":"National Collaborating Centre for Mental Health","year":"2009","unstructured":"National Collaborating Centre for Mental Health. Borderline personality disorder: treatment and management. editor. Leicester: British Psycholog. Soc. [u.a.]; 2009. p. 555. (National clinical practice guideline).","edition":"editor"},{"key":"3451_CR70","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/15622975.2021.2013041","volume":"23","author":"J Sarris","year":"2022","unstructured":"Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23:424\u201355.","journal-title":"World J Biol Psychiatry"},{"key":"3451_CR71","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/1028415X.2022.2077031","volume":"26","author":"FC Gabriel","year":"2023","unstructured":"Gabriel FC, Oliveira M, Bruna De MM, Berk M, Brietzke E, Jacka FN, et al. Nutrition and bipolar disorder: A systematic review. Nutr Neurosci. 2023;26:637\u201351.","journal-title":"Nutr Neurosci"},{"key":"3451_CR72","doi-asserted-by":"publisher","first-page":"21m14176","DOI":"10.4088\/JCP.21m14176","volume":"83","author":"M Pompili","year":"2022","unstructured":"Pompili M, Erbuto D, Innamorati M, Luciano M, Sampogna G, Abbate-Daga G, et al. The relationship between mental pain, suicide risk, and childhood traumatic experiences: results from a multicenter study. J Clin Psychiatry. 2022;83:21m14176.","journal-title":"J Clin Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03451-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:02:35Z","timestamp":1779282155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3451"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03451-4","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Supplementary information is available at MP\u2019s website. The supplementary information contains the study protocol, selection and inclusion criteria, detailed characteristics of the studies, network graphs, forest plots, and league tables for efficacy, discontinuation rates, and tolerability outcomes. It also includes data on consistency, the quality of evidence, the transitivity assumption, and sensitivity analyses. Additional variables can be shared upon request to the corresponding author, with the agreement of Dr. Guillaume Fond and Dr. Cyril Gerolymos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Access to data"}}]}}